The 2027 Pershing Square Sohn Cancer Prize supports early-career scientists pursuing bold, high-risk research to advance cancer understanding, diagnosis, prevention, or treatment and address unmet needs.
The application portal for the 2027 Pershing Square Sohn Cancer Prize has closed; the Letter of Intent deadline was Monday, October 26, 2026, at 5:00 p.m. ET.
Funder: Pershing Square Philanthropies
Due Dates (Anticipated): October 2027 (Letter of Intent)
Funding Amounts: $750,000 over three years ($250,000 annually, including indirect costs)
Summary: Supports early-career scientists pursuing scientifically sound, high-risk cancer research with potential to shift paradigms or address unmet needs.
Key Information: Applicants need two to six years running an independent laboratory and an eligible U.S. nonprofit research appointment.
The Pershing Square Sohn Cancer Research Alliance (PSSCRA) supports early-career scientists pursuing bold cancer research at a stage when traditional funding may be lacking. The Prize favors radically innovative, scientifically sound projects with strong rationales and novel methodologies, including basic research and technological applications. Its goal is to advance the understanding, diagnosis, prevention, or treatment of cancer through work that could shift existing paradigms or address unmet needs.
The program supports investigators at institutions across the United States, rather than only the greater New York City area. Alongside research funding, winners gain access to facilitated research partnerships, industry mentors, philanthropic and for-profit investors, an annual retreat, and opportunities to present ideas at conferences and events. These activities connect scientific discovery with the business community and early-stage biomedical investment.